2025-03-19 Gan & Lee Pharmaceuticals Announced First Participant Dosed in a Phase 3 Clinical Study (SUPER-2) of Once-weekly Basal Insulin GZR4 injection in Chinese Patients with type 2 diabetes Mellitus MORE
Focused on improving human health and adhering to the corporate culture of "Science & Excellence", Gan & Lee is dedicated to protecting the health of people with diabetes.Our Product Long-acting insulin Basalin® Fast-acting insulin Prandilin® Rapilin® Xiulin...
Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in a Phase 2... Dec 18, 2024, 06:01 ETGan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-...
agonist independently developed by the company, in adult overweight/obese patients in China were presented as an oral presentation at ObesityWeek®️ 2024. Statement: GZR18 is an investigational drug and is not approved for use in any country. Gan & Lee Pharmaceuticals does not endorse the u...
10/16, 甘李药业 (Gan & Lee Pharmaceuticals)的三款在研疗法——GZR18、GZR4和GZR101——在中国II期研究中取得了针对2型糖尿病的良好中期结果,显示出在降低糖化血红蛋白(HbA1c)和改善其他血糖控制指标方面,优于或相当于其比较药物的疗效。GZR18是一种每两周注射
/PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Bolsa de Valores de Shanghai: 603087) anunció los resultados del estudio clínico de fase 1b/2a del...
Gan & Lee Pharmaceuticals Jiangsu Co., Ltd. A wholly-owned subsidiary of the Company, established in Taizhou, Jiangsu Province in China, 2015 Main Business: Chemical production base, which has a polypeptide synthesis raw material medicine production line, a solid oral preparation production line (...
About Gan & Lee Founded in 1998, Gan & Lee Pharmaceuticals has successfully developed the first Chinese domestic insulin analog. The company has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment....
Use Futu NiuNiu to view Gan & Lee Pharmaceuticals. (603087)'s stock price, real-time quotes, latest news, historical trend charts, financial information and quotes.
10/16,甘李药业(Gan & Lee Pharmaceuticals)的三款在研疗法——GZR18、GZR4和GZR101——在中国II期研究中取得了针对2型糖尿病的良好中期结果,显示出在降低糖化血红蛋白(HbA1c)和改善其他血糖控制指标方面,优于或相当于其比较药物的疗效。GZR18是一种每两周注射一次的GLP-1受体激动剂,GZR4是一种每周一次注射...